NCT04519502

Brief Summary

A cohort study of women who deliver at select sites on randomly selected days in 2019 and 2020, and all confirmed COVID-19 infections among pregnant or immediately postpartum women in 2020. The study population includes approximately 24,400 deliveries on randomly selected days in 2019 and 2020, and an additional 1000-2100 confirmed COVID-19 infections among pregnant women or immediately postpartum.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
25,604

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started Jun 2020

Geographic Reach
1 country

12 active sites

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

June 23, 2020

Completed
2 months until next milestone

First Submitted

Initial submission to the registry

August 18, 2020

Completed
1 day until next milestone

First Posted

Study publicly available on registry

August 19, 2020

Completed
1 year until next milestone

Primary Completion

Last participant's last visit for primary outcome

August 31, 2021

Completed
2 months until next milestone

Study Completion

Last participant's last visit for all outcomes

November 4, 2021

Completed
Last Updated

March 27, 2023

Status Verified

March 1, 2023

Enrollment Period

1.2 years

First QC Date

August 18, 2020

Last Update Submit

March 24, 2023

Conditions

Outcome Measures

Primary Outcomes (1)

  • Maternal Mortality and Morbidity Composite

    Percentage of patients with at least one of the following: mortality, morbidity related to hypertensive disorders of pregnancy, morbidity related to postpartum hemorrhage, morbidity related to infection

    During pregnancy through 6 weeks postpartum

Secondary Outcomes (10)

  • Cesarean Delivery

    Delivery

  • Severe maternal morbidity or mortality

    During pregnancy through 6 weeks postpartum

  • Adverse maternal outcomes

    During pregnancy through 6 weeks postpartum

  • Adverse neonatal outcomes

    Delivery through hospital discharge up to 120 days

  • Neonatal infection

    Delivery through hospital discharge up to 120 days

  • +5 more secondary outcomes

Study Arms (3)

Randomly Selected Delivery Dates 2019

Women who deliver at one of the MFMU Network hospitals on randomly selected days between March 1 and December 31, 2019.

Randomly Selected Delivery Dates 2020

Women who deliver at one of the MFMU Network hospitals on randomly selected days between March 1 and December 31, 2020

Confirmed COVID-19 Infections

Women with confirmed COVID-19 infection between March 1, 2020 and December 31, 2020 and who delivered on or before December 31, 2020.

Eligibility Criteria

Sexfemale
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)
Sampling MethodProbability Sample
Study Population

Approximately 24,400 deliveries on randomly selected days in 2019 and 2020, and an additional 1000-2100 confirmed COVID-19 infections among pregnant women or immediately postpartum

You may qualify if:

  • Women who deliver at a selected hospital participating in the MFMU Network on selected dates sent by the Data Coordinating Center from March 1, 2019, through Dec, 31, 2019. Women delivered in the calendar year 2019 will serve as the controls (before pandemic).
  • Women who deliver at a selected hospital participating in the MFMU Network on selected dates sent by the Data Coordinating Center from March 1, 2020, through Dec, 31, 2020. Women delivered in the calendar year 2020 will be considered as deliveries during the pandemic (research question 1) and non-confirmed positives as controls (research question 2).
  • Pregnant and postpartum (within 6 weeks of delivery) women with confirmed COVID-19 infection from March 1, 2020, through Dec, 31, 2020 and who deliver on or before December 31, 2020. Both those with COVID-19 infection requiring in-patient management and those managed as out-patients will be included. Confirmed COVID-19 infection is defined as a positive COVID-19 viral (i.e., nucleic acid or antigen tests) test during pregnancy through 42 days postpartum.

You may not qualify if:

  • Multifetal gestation higher than twins

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (12)

University of Alabama - Birmingham

Birmingham, Alabama, 35233, United States

Location

Northwestern University

Chicago, Illinois, 60611, United States

Location

Columbia University-St. Luke's Hospital

New York, New York, 10032, United States

Location

University of North Carolina-Chapel Hill

Chapel Hill, North Carolina, 17599, United States

Location

Case Western Reserve University

Cleveland, Ohio, 44109, United States

Location

Ohio State University

Columbus, Ohio, 43210, United States

Location

Hospital of the University of Pennsylvania

Philadelphia, Pennsylvania, 19104, United States

Location

Magee Women's Hospital

Pittsburgh, Pennsylvania, 15213, United States

Location

Brown Univeristy

Providence, Rhode Island, 02905, United States

Location

University of Texas Medical Branch

Galveston, Texas, 77555, United States

Location

University of Texas - Houston

Houston, Texas, 77030, United States

Location

University of Utah Medical Center

Salt Lake City, Utah, 84132, United States

Location

Related Publications (1)

  • Metz TD, Clifton RG, Hughes BL, Sandoval GJ, Grobman WA, Saade GR, Manuck TA, Longo M, Sowles A, Clark K, Simhan HN, Rouse DJ, Mendez-Figueroa H, Gyamfi-Bannerman C, Bailit JL, Costantine MM, Sehdev HM, Tita ATN, Macones GA; Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) Maternal-Fetal Medicine Units (MFMU) Network. Association Between Giving Birth During the Early Coronavirus Disease 2019 (COVID-19) Pandemic and Serious Maternal Morbidity. Obstet Gynecol. 2023 Jan 1;141(1):109-118. doi: 10.1097/AOG.0000000000004982. Epub 2022 Oct 27.

MeSH Terms

Conditions

COVID-19Pregnancy Complications

Condition Hierarchy (Ancestors)

Pneumonia, ViralPneumoniaRespiratory Tract InfectionsInfectionsVirus DiseasesCoronavirus InfectionsCoronaviridae InfectionsNidovirales InfectionsRNA Virus InfectionsLung DiseasesRespiratory Tract DiseasesFemale Urogenital Diseases and Pregnancy ComplicationsUrogenital Diseases

Study Officials

  • Monica Longo, MD

    Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

    STUDY DIRECTOR
  • Torri Metz, MD

    University of Utah Medical Center

    STUDY CHAIR

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
RETROSPECTIVE
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

August 18, 2020

First Posted

August 19, 2020

Study Start

June 23, 2020

Primary Completion

August 31, 2021

Study Completion

November 4, 2021

Last Updated

March 27, 2023

Record last verified: 2023-03

Data Sharing

IPD Sharing
Will share

Data will be shared per NIH policy.

Shared Documents
STUDY PROTOCOL

Locations